RAF and MEK Inhibitors in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) remains a major global health concern.
• The receptor tyrosine kinase-RAS-mitogen-activated protein kinase (RTK-RAS-MAPK) pathway is crucial in NSCLC pathogenesis.
• Activating mutations in BRAF are less common drivers in NSCLC compared to KRAS.

Purpose of the Study:

• To review the current landscape of RAF and MEK inhibition in NSCLC management.
• To explore the therapeutic potential and challenges of RAF-MEK inhibitors in BRAFV600E-mutant NSCLC.
• To highlight the development of novel RAF and MEK inhibitors.

Main Methods:

• Literature review of preclinical and clinical studies on RAF and MEK inhibitors in NSCLC.
• Analysis of regulatory approvals and clinical trial data for approved RAF-MEK inhibitor combinations.
• Examination of mechanisms of acquired resistance to RAF-MEK inhibitors.

Main Results:

• RAF-MEK inhibitor combinations (dabrafenib-trametinib, encorafenib-binimetinib) are approved for BRAFV600E-mutant NSCLC.
• These targeted therapies represent a breakthrough but are limited by acquired resistance.
• New RAF and MEK inhibitors with improved profiles are under investigation.

Conclusions:

• RAF and MEK inhibitors offer a targeted approach for a subset of NSCLC patients.
• Overcoming acquired resistance is critical for maximizing the clinical benefit of these agents.
• Ongoing research into novel inhibitors holds promise for future NSCLC treatment strategies.